Pura Vida Investments’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY.RT
PCM
ACM
FCM
BFS
LGP
CS
LCM
NCM
Pura Vida Investments's BMY.RT Position: Q4 2020 in Review
Pura Vida Investments sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 886,222 shares — an estimated $1.99M sold.
Pura Vida Investments first reported a position in BMY.RT in Q1 2020 and held it in 3 quarters. The position peaked at $1.99M in Q3 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.
- Pura Vida Investments reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
- Pura Vida Investments sold 886,222 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $1.99M.
- Pura Vida Investments first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 3 quarters.
- Pura Vida Investments's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.99M in Q3 2020.
- 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.
Based on Pura Vida Investments's 13F filing for Q4 2020, filed 16 Feb 2021.